Literature DB >> 34315806

Short stature and combined immunodeficiency associated with mutations in RGS10.

Ivan K Chinn1, Zhihui Xie2, Eunice C Chan2, Bianca M Nagata3, Alexey Koval4,5, Wei-Sheng Chen2, Fan Zhang6, Sundar Ganesan7, Diana N Hong1, Motoshi Suzuki8, Glenn Nardone8, Ian N Moore3, Vladimir L Katanaev4,5, Andrea E Balazs1, Chengyu Liu6, James R Lupski9,10, Jordan S Orange11, Kirk M Druey12.   

Abstract

We report the clinical and molecular phenotype of three siblings from one family, who presented with short stature and immunodeficiency and carried uncharacterized variants in RGS10 (c.489_491del:p.E163del and c.G511T:p.A171S). This gene encodes regulator of G protein signaling 10 (RGS10), a member of a large family of GTPase-activating proteins (GAPs) that targets heterotrimeric G proteins to constrain the activity of G protein-coupled receptors, including receptors for chemoattractants. The affected individuals exhibited systemic abnormalities directly related to the RGS10 mutations, including recurrent infections, hypergammaglobulinemia, profoundly reduced lymphocyte chemotaxis, abnormal lymph node architecture, and short stature due to growth hormone deficiency. Although the GAP activity of each RGS10 variant was intact, each protein exhibited aberrant patterns of PKA-mediated phosphorylation and increased cytosolic and cell membrane localization and activity compared to the wild-type protein. We propose that the RGS10 p.E163del and p.A171S mutations lead to mislocalization of the RGS10 protein in the cytosol, thereby resulting in attenuated chemokine signaling. This study suggests that RGS10 is critical for both immune competence and normal hormonal metabolism in humans and that rare RGS10 variants may contribute to distinct systemic genetic disorders.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34315806      PMCID: PMC8522579          DOI: 10.1126/scisignal.abc1940

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   9.517


  76 in total

1.  RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling.

Authors:  Xiaoguang Sun; Kevin M Kaltenbronn; Thomas H Steinberg; Kendall J Blumer
Journal:  Mol Pharmacol       Date:  2004-11-24       Impact factor: 4.436

2.  Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2).

Authors:  Adam J Kimple; Meera Soundararajan; Stephanie Q Hutsell; Annette K Roos; Daniel J Urban; Vincent Setola; Brenda R S Temple; Bryan L Roth; Stefan Knapp; Francis S Willard; David P Siderovski
Journal:  J Biol Chem       Date:  2009-05-28       Impact factor: 5.157

3.  RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes.

Authors:  Magali Berthebaud; Christel Rivière; Peggy Jarrier; Adlen Foudi; Yanyan Zhang; Daniel Compagno; Anne Galy; William Vainchenker; Fawzia Louache
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

Review 4.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2019-05-21       Impact factor: 31.745

Review 5.  Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.

Authors:  Katherine E Squires; Carolina Montañez-Miranda; Rushika R Pandya; Matthew P Torres; John R Hepler
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

6.  Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1.

Authors:  C K Chen; M E Burns; W He; T G Wensel; D A Baylor; M I Simon
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

Review 7.  A gene-based review of RGS4 as a putative risk gene for psychiatric illness.

Authors:  Emanuel Schwarz
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-05-24       Impact factor: 3.568

Review 8.  PI3K pathway defects leading to immunodeficiency and immune dysregulation.

Authors:  Cristiane J Nunes-Santos; Gulbu Uzel; Sergio D Rosenzweig
Journal:  J Allergy Clin Immunol       Date:  2019-05       Impact factor: 10.793

9.  Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.

Authors:  Gabriel D Victora; David Dominguez-Sola; Antony B Holmes; Stephanie Deroubaix; Riccardo Dalla-Favera; Michel C Nussenzweig
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

Review 10.  Glucagon and cyclic AMP: time to turn the page?

Authors:  Robert L Rodgers
Journal:  Curr Diabetes Rev       Date:  2012-09
View more
  2 in total

1.  Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease.

Authors:  Gonzalo P Solis; Tatyana V Kozhanova; Alexey Koval; Svetlana S Zhilina; Tatyana I Mescheryakova; Aleksandr A Abramov; Evgeny V Ishmuratov; Ekaterina S Bolshakova; Karina V Osipova; Sergey O Ayvazyan; Sébastien Lebon; Ilya V Kanivets; Denis V Pyankov; Sabina Troccaz; Denis N Silachev; Nikolay N Zavadenko; Andrey G Prityko; Vladimir L Katanaev
Journal:  Cells       Date:  2021-10-14       Impact factor: 6.600

2.  Gαi2-induced conductin/axin2 condensates inhibit Wnt/β-catenin signaling and suppress cancer growth.

Authors:  Cezanne Miete; Gonzalo P Solis; Alexey Koval; Martina Brückner; Vladimir L Katanaev; Jürgen Behrens; Dominic B Bernkopf
Journal:  Nat Commun       Date:  2022-02-03       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.